FLUDARABINE PHOSPHATE clinical trials
4 indexed studies · 1 currently recruiting
- AuthorisedPhase I and Phase II (Integrated)- First administration to humans
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)
This study is testing a new treatment (CCTx-001) for adults with acute myeloid leukaemia (AML) that has returned or not responded to previous treatments. It aims to find the right dose and check how safe and effective it is.
For: Relapsed/Refractory Acute Myeloid Leukemia (AML)Germany · Spain · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
This study is testing an immunotherapy called LN-145 for women with cervical cancer that has come back, spread, or hasn't responded to other treatments. It's looking at how well the treatment shrinks tumours and if it's safe to use.
For: Recurrent · metastatic · or persistent Cervical CarcinomaGermany · Netherlands · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
This study is testing a new cell therapy called durcabtagene autoleucel for adults with multiple myeloma that has come back or isn't responding to other treatments. It aims to see how well the treatment shrinks the cancer and improves patients' health.
For: Adult patients with relapsed and refractory multiple myelomaSpain · Greece · Italy - Not yet recruitingPHASE2
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
This study is looking at a new medicine called Zola-cel (BMS-986353) for adults with specific blood conditions: chronic immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). The goal is to see if it's safe and helps improve these conditions.
For: Chronic Immune Thrombocytopenia · Autoimmune Hemolytic AnemiaUnited States · Denmark · Germany